Arthur Hayes Shifts From Crypto to Biohacking From Trading Floors to Health Labs

Arthur Hayes, co-founder of BitMEX, has lived a whirlwind career. He built one of the largest crypto trading platforms in the world, faced legal battles, and later received a presidential pardon. Today, Hayes is moving his focus from digital assets to longevity investments. This crypto biohacking shift marks a new phase of his journey, where financial success fuels his pursuit of health and extended life.

Hayes Embraces Stem Cell Therapy

Instead of limiting himself to crypto markets, Hayes has taken a bold step into the biohacking space. He recently invested in a stem cell company with clinics in Mexico and Bangkok. For over a year, he has traveled frequently to these clinics for stem cell infusions aimed at extending his healthspan.

In a recent video interview, Hayes explained his motivation. “I want to live as long as possible, as healthy as possible,” he said. He believes stem cell therapy represents the future, noting that more countries are beginning to relax regulations around its use. His crypto biohacking shift highlights how top executives are now using their wealth to challenge traditional health boundaries.

A Presidential Pardon and a New Path

Earlier this year, former U.S. President Donald Trump pardoned Hayes along with BitMEX co-founders Benjamin Delo and Samuel Reed. The three had been charged in 2020 for violating the Bank Secrecy Act. By 2022, they pleaded guilty, paid $10 million each, and received probation.

Even before the pardon, Hayes was living comfortably in Singapore and spending part of the year skiing in Japan. His widely read essays on markets, meme culture, and monetary theory continued to influence crypto circles. In fact, one of his posts in 2023 inspired the creation of Ethena’s synthetic dollar, now the third-largest stablecoin by market value.

Yet, despite these accomplishments, his crypto biohacking shift shows that his ambitions stretch far beyond financial markets.

Crypto Wealth Meets Longevity Dreams

Hayes is not alone in this new pursuit. Other industry leaders are also pouring capital into health and biotech. Ethereum co-founder Vitalik Buterin has donated millions to life-extension research. Coinbase CEO Brian Armstrong co-founded NewLimit, a genetic engineering startup that recently raised $130 million. Former Coinbase CTO Balaji Srinivasan has also invested heavily in biotech.

The crypto biohacking shift is therefore not a personal decision alone. Instead, it represents a broader movement among crypto pioneers who want to live longer while continuing to disrupt industries.

Market Shifts and New Risks

Alongside health ventures, Hayes continues to watch crypto markets closely. His family office, Maelstrom, has backed three digital asset treasury companies (DATs). These firms accumulate crypto on their balance sheets and now hold nearly $110 billion worth of Bitcoin, according to CoinGecko.

However, Hayes has warned that the surge in DATs could overheat the market. He argues that only those that can attract passive institutional investors will succeed. Otherwise, many treasury companies risk trading at discounts, which could destabilize the broader rally.

The Future of Hayes’s Journey

Arthur Hayes’s story reflects how crypto pioneers are evolving. After reshaping finance, many are now testing how far they can push in sectors such as biotech, education, and AI. Hayes’s crypto biohacking shift shows that his future lies not just in tokens, but also in science that challenges the limits of human longevity.

Whether stem cells prove transformative or not, his move signals that wealth from the crypto boom is flowing into new frontiers. Just as Hayes once disrupted traditional finance, he now aims to disrupt traditional healthcare.

#ArthurHayes#Biohacking#LongevityCryptoDigitalAssets